LBL-003
/ Leads Biolabs
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
May 21, 2024
Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies
(clinicaltrials.gov)
- P1 | N=18 | Completed | Sponsor: Nanjing Leads Biolabs Co.,Ltd | Recruiting ➔ Completed | N=36 ➔ 18
Enrollment change • Trial completion • Oncology • Solid Tumor
December 11, 2023
Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Dec 2023 ➔ Jul 2024 | Trial primary completion date: Oct 2023 ➔ Mar 2024
Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor
November 21, 2022
Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Nanjing Leads Biolabs Co.,Ltd | Trial primary completion date: Oct 2022 ➔ Oct 2023
Trial primary completion date • Oncology • Solid Tumor
December 10, 2021
Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies
(clinicaltrials.gov)
- P1; N=36; Recruiting; Sponsor: Nanjing Leads Biolabs Co.,Ltd; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Oncology • Solid Tumor
September 13, 2021
Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies
(clinicaltrials.gov)
- P1; N=36; Not yet recruiting; Sponsor: Nanjing Leads Biolabs Co.,Ltd
Clinical • New P1 trial • Oncology • Solid Tumor
1 to 5
Of
5
Go to page
1